Special considerations for the use of pathogen reduced blood components in pediatric patients: An overview

Transfusion and Apheresis Science

Volumn 57, Issue 3, 2018, Pages 374-377

  Goodrich, Raymond P ^a   Segatchian, Jerard ^b  

^a Veterinary Dentistry and Oral Surgery   (United States)

^b International Consultancy in Blood Components Quality Safety Improvement   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE EVENT; BLOOD ANALYSIS; BLOOD COMPONENT; BLOOD SAFETY; BLOOD TOXICITY; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; CLINICAL PRACTICE; COST BENEFIT ANALYSIS; ERYTHROCYTE TRANSFUSION; HUMAN; INFECTIOUS AGENT; PATIENT SAFETY; PEDIATRICS; PLASMA TRANSFUSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; THERAPY EFFECT; THROMBOCYTE TRANSFUSION; ADOLESCENT; BLOOD COMPONENT THERAPY; CHILD; PRESCHOOL CHILD; PROCEDURES;

ADOLESCENT; BLOOD COMPONENT TRANSFUSION; CHILD; CHILD, PRESCHOOL; HUMANS;

EID: 85047087677     PISSN: 14730502     EISSN: 18781683     Source Type: Journal    
DOI: 10.1016/j.transci.2018.05.022     Document Type: Review

References (19)

1. Perkins, H.A., Busch, M.P., Transfusion-associated infections: 50 years of relentless challenges and remarkable progress. Transfusion 50:10 (2010), 2080–2099.
2. Jacquot, C., Delaney, M., Efforts toward elimination of infectious agents in blood products. J Intensive Care Med(Jannuary), 2018, 10.1177/0885066618756589 885066618756589.
3. Mundt, J.M., Rouse, L., Van den Bossche, J., Goodrich, R.P., Chemical and biological mechanisms of pathogen reduction technologies. Photochem Photobiol 90:5 (2014), 957–964.
4. Horowitz, B., Lazo, A., Grossberg, H., Page, G., Lippin, A., Swan, G., Virus inactivation by solvent/detergent treatment and the manufacture of SD-plasma. Vox Sang 74:Suppl. 1 (1998), 203–206 [Review].
5. Kühnel, D., Müller, S., Pichotta, A., Radomski, K.U., Volk, A., Schmidt, T., Inactivation of Zika virus by solvent/detergent treatment of human plasma and other plasma-derived products and pasteurization of human serum albumin. Transfusion 57:March (3pt2) (2017), 802–810, 10.1111/trf.13964 [Epub 2016 Dec 26].
6. Goodrich, R.P., Ignorance is not bliss. Transfusion 58:March (3) (2018), 615–616, 10.1111/trf.14486.
7. AuBuchon, J., Mortality risks, costs, and decision making in transfusion medicine. Am J Clin Pathol 115:Junuary (6) (2001), 934–936.
8. Estcourt, L.J., Malouf, R., Hopewell, S., Trivella, M., Doree, C., Stanworth, S.J., et al. Pathogen-reduced platelets for the prevention of bleeding. Cochrane Database Syst Rev, 7(July), 2017, CD009072, 10.1002/14651858.CD009072.pub3 [Review].
9. Salunkhe, V., van der Meer, P.F., de Korte, D., Seghatchian, J., Gutie´rrez, L., Development of blood transfusion product pathogen reduction treatments: a review of methods, current applications and demands. Transfus Apher Sci 52:1 (2015), 19–34.
10. Trakhtman, P., Karpova, O., Balashov, D., Kurnikova, E., Pirumova, V., Starostin, N., Rumiantsev, A., Efficacy and safety of pathogen-reduced platelet concentrates in children with cancer: a retrospective cohort study. Transfusion 56:March (Suppl. 1) (2016), S24–8, 10.1111/trf.13332.
11. Rebulla, P., Vaglio, S., Beccaria, F., Bonfichi, M., Carella, A., Chiurazzi, F., et al. Clinical effectiveness of platelets in additive solution treated with two commercial pathogen-reduction technologies. Transfusion 57:May (5) (2017), 1171–1183, 10.1111/trf.14042 [Epub 2017 Feb 24].
12. US Food and Drug Administration, PMA BP140143: FDA Summary of Safety and Effectiveness Data. December 18, 2014.
13. Reddy, H., Dayan, A.D., Cavagnaro, J., Gad, S., Li, J., Goodrich, R., Toxicity testing of the mirasol PRT process for platelets and plasma: a novel riboflavin-based pathogen reduction technology for blood transfusion safety. Transfus Med Rev 22:2 (2008), 133–153.
14. Ciaravino, V., McCullough, T., Dayan, A.D., Pharmacokinetic and toxicology assessment of INTERCEPT (S-59 and UVA treated) platelets. Hum Exp Toxicol 20:October (10) (2001), 533–550 Review.
15. Allain, J.P., Owusu-Ofori, A.K., Assennato, S.M., Marschner, S., Goodrich, R.P., et al. Effect of plasmodium inactivation in whole blood on the incidence of blood transfusion-transmitted malaria in endemic regions: the African Investigation of the Mirasol System (AIMS) randomised controlled trial. Lancet 387:10029 (2016), 1753–1760.
16. Pomeyie, C., JICA invests in Ghana's health sector; Ghana News agency; Thursday, 1st September. 2016 http://www.ghananewsagency.org/economics/jica-invests-in-ghana-s-health-sector-107437.
17. Solheim, B.G., Pathogen reduction of blood components. Transfus Apher Sci 39:1 (2008), 75–82.
18. McCullough, J., Progress toward a pathogen-free blood supply. Clin Infect Dis 37:1 (2003), 88–95.
19. Nkohkwo, A., Agbor, G., Asongalem, E., Tagny, C., Asonganyi, T., Whole blood pathogen reduction technology and blood safety in sub-Saharan Africa: a systematic review with regional discussion. Afr J Lab Med, 5(June (1)), 2016, 363, 10.4102/ajlm.v5i1.363 eCollection 2016. [Review].